Delcath Systems' phase III trial for inoperable cancer is planned at Sydney Melanoma Unit.
D000046:Academic Medical Centers / Q000379:methods; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017326:Clinical Trials, Phase III as Topic / Q000379:methods*; D004317:Doxorubicin / Q000008:administration & dosage; D016503:Drug Delivery Systems / Q000379:methods*; D004345:Drug Industry / Q000379:methods*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy*; D009517:New South Wales; D010044:Outpatient Clinics, Hospital
D000970:Antineoplastic Agents; D004317:Doxorubicin